Meeting
2013 ASCO Annual Meeting
Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics.
Authors
Heikki Joensuu
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
Heikki Joensuu , Paolo Giovanni Casali , Peter Reichardt , Yoon-Koo Kang , Jean-Yves Blay , Piotr Rutkowski , Hans Gelderblom , Peter Hohenberger , Michael Gordon Leahy , Margaret von Mehren , Giuseppe Badalamenti , Martin E. Blackstein , Axel Le Cesne , Patrick Schoffski , Robert G. Maki , Jian-Ming Xu , Toshirou Nishida , Christian Kappeler , Iris Kuss , George D. Demetri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Clinical Trial Registration Number
NCT01271712
Citation
J Clin Oncol 31, 2013 (suppl; abstr 10551)
DOI
10.1200/jco.2013.31.15_suppl.10551
Abstract #
10551
Poster Bd #
45A
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
First Author: Michael C. Heinrich
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs).
First Author: Suzanne George
Poster
2022 ASCO Annual Meeting
Platelet derived growth factor receptor alpha (PDGFRA) mutant gastrointestinal stromal tumours (GISTs): Clinicopathological characteristics and outcomes from a regional centre in the United Kingdom.
First Author: David M Favara
Poster
2021 ASCO Annual Meeting
Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).
First Author: Yoshitaka Honma